The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.

导出 OA

翻译打印收藏纠错

作者： Silvia,Piantoni ^[1] ; Enrico,Colombo ^[2] ; Paolo,Airò ^[3] ; Angela,Tincani ^[4] ; Antonio,Brucato ^[4] ; Franco,Franceschini ^[5] ; Laura,Andreoli ^[6] ; Roberto,Furloni ^[4] ; Mirko,Scarsi ^[5]

作者单位： Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy. slv.piantoni@gmail.com. ^[1] Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. slv.piantoni@gmail.com. ^[2] Internal Medicine Department, ASST Valcamonica, Esine, Brescia, Italy. ^[3] Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy. ^[4] Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. ^[5] Department of Biomedical and Clinical Sciences "Sacco", University of Milano, Ospedale Fatebenefratelli, Milano, Italy. ^[6]

主题词秋水仙碱(Colchicine);冠状病毒感染(Coronavirus Infections);人类(Humans);疾病大流行(Pandemics);肺炎, 病毒性(Pneumonia, Viral)

DOI 10.1007/s10067-020-05232-y

PMID 32564213

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交